CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising ...

CG Oncology, Inc. (CGON) closed the last trading session at $29.61, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) shares were down 6.9% during mid-day trading on Monday .The stock traded as low as $27.84 and last traded at $27.98. Approximately 108,925 ...

CG Oncology has a 1-year low of $25.77 and a 1-year high of $50.23. Get CG Oncology alerts: CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings results on Tuesday ...

TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene is differentiated by its “superior” efficacy and ...

The consensus price target hints at a 123.3% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

CG Oncology, Inc. is an Irvine, California based late-clinical-stage biopharmaceutical concern focused on the development of cretositimogene for the treatment of non-muscle invasive bladder cancer ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...